The Quidel Value Build (QVB™) programs are the strategic platform from which we are strengthening our position of rapid diagnostics leadership, and providing evidence to support the increasingly important role that point-of-care testing plays in healthcare decision making and outcomes.

Completion of Clinical and Economic Studies

The results of a point-of-care test may have a significant impact on the type, level and cost of subsequent patient treatment. In fact, as many as 70% of treatment decisions are based on the results of diagnostic tests—which account for only 5-6% of a typical hospital's budget. This means healthcare professionals increasingly depend upon the QuickVue brand to give them the confidence to set the course of treatment.

Partnerships with medical advisors, government agencies, professional societies

In order to help us make decisions regarding new diagnostic tests, three Medical Advisory Boards were formed in 2005. They will provide insight within their areas of expertise and will take an active role in discussions we will have in the public health arena.

Market leadership activities

Quidel's manufacturing infrastructure, distribution network and industry-leading brand name allow us to acquire new point-of-care technologies and achieve widespread, cost-effective introduction to the market.